Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ba4a20a688da39aa0585695f8b826fd |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-00 |
filingDate |
2010-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_050ae8512f8f4bcc85c47641354a64af |
publicationDate |
2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8071585-B2 |
titleOfInvention |
Therapeutic agents |
abstract |
A compound (2S)-2-[1-(2,6-dichlorophenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-(3-hydroxyazetidin-1-yl)-N-(5-methylpyrazin-2-yl)propanamide is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion. |
priorityDate |
2009-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |